Loading
San Francisco oncologist who was lead author of KEYNOTE-966, which showed that adding pembrolizumab to gemcitabine and cisplatin helps people with advanced bile duct cancer live longer.
Robin Kate Kelley is a gastrointestinal medical oncologist at UCSF who focuses on liver and biliary cancers. She was first author of the 2023 Lancet report of KEYNOTE-966, in which pembrolizumab plus gemcitabine and cisplatin improved overall survival in advanced biliary tract cancer, and has led early trials of immunotherapy combinations in hepatocellular carcinoma, including the cabozantinib and atezolizumab study COSMIC-312.
| Title | Journal | Year |
|---|---|---|
| KEYNOTE-966: pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer | The Lancet | 2023 |
Shares Intrahepatic cholangiocarcinoma, Hepatocellular carcinoma and the tags biliary, hcc, trialist.
Shares Hepatocellular carcinoma and the tags biliary, hcc, trialist.
Shares Biliary tract cancer (all types) and the tags biliary, trialist.
Shares Hepatocellular carcinoma and the tags hcc, trialist.
Shares Intrahepatic cholangiocarcinoma, Biliary tract cancer (all types) and the tags biliary, trialist.
Shares Biliary tract cancer (all types) and the tags biliary, trialist.
Shares Hepatocellular carcinoma and the tags hcc, trialist.
Shares Biliary tract cancer (all types) and the tags biliary, trialist.